Bob LINKE, MBA

Bob is a biopharma entrepreneur building and leading emerging companies raising over $75M in private and non-dilutive capital. Bob serves as CEO of Osmol Therapeutics, developing Yale School of Medicine technolgy to address chemotherapy induced peripheral neuropathy, a condition with no approved treatments that most significantly impacts breast cancer patients, the Company’s initial focus. In addition, he is the Executive Chairman of Embera NeuroTherapeutics and until 2022, IonSense, when it was successfully acquired by Bruker. His early career was spent in big pharma at Baxter, developing and commercializing pharmaceuticals and delivery systems. He received his MBA from Harvard Business School.